Management ATG (SIRS)

Francesca Bonifazi

doi:10.1007/978-3-030-02278-5_26

Management ATG (SIRS)

Review

In: The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet]. 7th edition. Cham (CH): Springer; 2019. Chapter 26.

Author

Francesca Bonifazi¹

Book Editors

Enric Carreras¹, Carlo Dufour², Mohamad Mohty³, Nicolaus Kröger⁴

Affiliation

¹ Institute of Hematology “Seràgnoli”, University Hospital S. Orsola-Malpighi, Bologna University, Bologna, Italy

Book Affiliations

¹ Spanish Bone Marrow Donor Registry, Josep Carreras Foundation and Leukemia Research Institute, Catalunya, Barcelona, Spain
² Hematology Unit, IRCCS Giannina Gaslini, Geneva, Switzerland
³ Department of Hematology, Pierre and Marie Curie University, Paris, France
⁴ Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppend, Hamburg, Germany

Excerpt

Currently horse and rabbit anti-lymphoglobulins (ATLG) or antithymocyte globulin (ATG) is available; the main, although not exclusive, use is for the treatment of aplastic anemia (horse) and for GVHD prophylaxis (rabbit).

Sections

Publication types

Review